- Associate Professor of Biochemistry and Molecular Biology, Indiana University School of Medicine South Bend, Adjunct Associate Professor of Chemistry and Biochemistry, University of Notre Dame
- Assistant Professor of Biochemistry and Molecular Biology, Indiana University School of Medicine South Bend, Adjunct Assistant Professor of Chemistry and Biochemistry, University of Notre Dame
- Research Assistant Professor, University of New Mexico
- Postdoctoral Fellow, University of New Mexico
- Ph.D. in Cell and Molecular Biology (Cell growth and Cancer), University of Pennsylvania
- B.S. in Cell and Molecular Biology, Texas Tech University
Ovarian cancer is the 5th leading cause of cancer death in women in the US. The vast majority of women (>70% in the US) diagnosed with ovarian cancer have advanced disease at the time of diagnosis (the tumor has spread or metastasized). For these women the survival rates are less that 25%. Importantly ovarian cancer is >90% curable if detected early (prior to metastatic spread). Unfortunately at this point in time we do not have a good understanding of ovarian cancer at the molecular level. The goal of my laboratory is to study the molecules that are important in promoting ovarian cancer progression. In particular I want to determine how a tumor “learns” how to metastasize so that we can better prevent, diagnose, and treat ovarian cancer.
One of the molecules involved in ovarian cancer progression is the epithelial growth factor receptor (EGFR). EGFR is overexpressed in at least 70% of ovarian cancer. Its expression correlates with poor survival rates. Over the past few years I have focused on the genes that are controlled by EGFR that regulate cancer progression. We are investigating how the ARID3B transcription factor is regulated by EGFR signaling and its involvement in cancer. ARID3B is a member of the ARID family of DNA binding proteins. We have found that ARID3B is overexpressed in ovarian cancer. By understanding the gene networks that are dysfunctional in ovarian cancer we will be better equipped to diagnose and treat this disease.
We are elucidating the role of ARID3B in normal differentiation and cancer progression. We intend to show 1) how is ARID3B regulated, 2) what are the ARID3B targets, 3) biochemical characterization of ARID3B functions, 4)how do these proteins contribute to normal cellular differentiation and cancer progression, and chemoresistance. Our data suggest that ARID3B is critical to development of several tissue types and that altered expression of ARID3B may contribute to cancer.
- Roy, L., Dahl, K.D.C. "Can stemness and chemoresistance be therapeutically targeted via signaling pathways in ovarian cancer?" 2018 Cancers, 10 (8), 0241.DOI: 10.3390/cancers10080241
- Nallathamby, P.D., Cowden-Dahl, K., Roeder, R.K. "Modular nanoparticle probes for personalized in vitro and in vivo imaging of cancer cell populations" 2017 Advanced Materials - TechConnect Briefs 2017, 3, pp. 122-125.
- Roeder, R.K., Curtis, T.E., Nallathamby, P.D., Irimata, L.E., McGinnity, T.L., Cole, L.E., Vargo-Gogola, T., Cowden Dahl, K.D. 'Nanoparticle imaging probes for molecular imaging with computed tomography and application to cancer imaging" 2017 Progress in Biomedical Optics and Imaging - Proceedings of SPIE, 10132, 101320X. DOI: 10.1117/12.2255688
- Kurkewich, J.L., Klopfenstein, N., Hallas, W.M., Wood, C., Sattler, R.A., Das, C., Tucker, H., Dahl, R., Dahl, K.D.C. "Arid3b Is Critical for B Lymphocyte Development" 2016 PLoS ONE, 11 (8), e0161468. DOI: 10.1371/journal.pone.0161468
- Bobbs, A., Gellerman, K., Hallas, W.M., Joseph, S., Yang, C., Kurkewich, J., Cowden Dahl, K.D. "ARID3B directly regulates ovarian cancer promoting genes" 2015 PLoS ONE, 10 (6), e0131961. DOI: 10.1371/journal.pone.0131961
- Mitra, A.K., Davis, D.A., Tomar, S., Roy, L., Gurler, H., Xie, J., Lantvit, D.D., Cardenas, H., Fang, F., Liu, Y., Loughran, E., Yang, J., Sharon Stack, M., Emerson, R.E., Cowden Dahl, K.D., Barbolina, M.V., Nephew, K.P., Matei, D., Burdette, J.E. "In vivo tumor growth of high-grade serous ovarian cancer cell lines" 2015 Gynecologic Oncology, 138 (2), pp. 372-377. DOI: 10.1016/j.ygyno.2015.05.040